Peer-reviewed papers from Q1 2020
Learn more about TRPV1, NaV1.7, variation between automated patch clamp platforms or TMEM16 and Cystic Fibrosis. See below papers from academic and pharma researchers, among others the CiPA consortium, AbbVie, Genentech, University of Queensland, Enterprise Therapeutics and many more.
Agwa, A. J. et Al. Manipulation of a spider peptide toxin alters its affinity for lipid bilayers and potency and selectivity for voltage-gated sodium channel subtype 1.7. J. Biol. Chem. 295, 5067–5080 (2020).
Choi, R. et Al. Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned. Int. J. Parasitol. (2020) doi:https://doi.org/10.1016/j.ijpara.2020.01.006.
Damann, N. et Al. In vitro characterization of the thermoneutral transient receptor potential vanilloid-1 (TRPV1) inhibitor GRTE16523. Eur. J. Pharmacol. 871, 172934 (2020).
Danahay, H. L. et Al. TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 201, 946–954 (2020).
Jalily, P. H. et Al. Put a cork in it: Plugging the M2 viral ion channel to sink influenza. Antiviral Res. 178, 104780 (2020).
Katavolos, P. et Al. Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs. Toxicol. Pathol. 48, 465–480 (2020).
Kramer, J. et Al. Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells. Sci. Rep. 10, 1–15 (2020).
Mueller, A. et Al. Mapping the Molecular Surface of the Analgesic Na V 1.7-Selective Peptide Pn3a Reveals Residues Essential for Membrane and Channel Interactions. ACS Pharmacol. Transl. Sci. (2020) doi:10.1021/acsptsci.0c00002.
Ridder et Al. (2020) “A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm”, Toxicology and Applied Pharmacology, Volume 395, 15 May 2020